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Abstract	  
	  
The	  pathophysiological	  mechanisms	  underlying	  Complex	   I	   (CI)	  deficiencies	  are	  understood	  only	  partially	  
which	   severely	   limits	   the	   treatment	   of	   this	   common,	   devastating,	  mitochondrial	   disorder.	   Recently,	  we	  
have	  shown	  that	  resveratrol	  (RSV),	  a	  natural	  polyphenol,	  has	  beneficial	  effects	  on	  CI	  deficiency	  of	  nuclear	  
origin.	  Here,	  we	  demonstrate	  that	  RSV	  is	  able	  to	  correct	  the	  biochemical	  defect	  in	  oxygen	  consumption	  in	  
five	  of	  thirteen	  CI-­‐deficient	  patient	  cell	   lines.	   	  Other	  beneficial	  effects	  of	  RSV	  include	  a	  decrease	  of	  total	  
intracellular	  ROS	  and	  the	  up-­‐regulation	  of	  the	  expression	  of	  mitochondrial	  superoxide	  dismutase	  (SOD2)	  
protein,	   a	   key	   antioxidant	   defense	   enzyme.	   The	  molecular	  mechanisms	   leading	   to	   the	   up-­‐regulation	   of	  
SOD2	   protein	   expression	   by	   RSV	   require	   the	   estrogen	   receptor	   (ER)	   and	   the	   estrogen-­‐related	   receptor	  
alpha	   (ERRα).	   Although	   RSV	   increases	   the	   level	   of	   SOD2	   protein	   in	   patients’	   fibroblasts,	   the	   enzyme	  
activity	   is	  not	   increased,	   in	  contrast	  to	  normal	  fibroblasts.	  This	   led	  us	  to	  hypothesize	  that	  SOD2	  enzyme	  
activity	  is	  regulated	  post-­‐translationally.	  This	  regulation	  involves	  SIRT3,	  a	  mitochondrial	  NAD+-­‐dependent	  
deacetylase	  and	  is	  critically	  dependent	  on	  NAD+	  levels.	  Taken	  together,	  our	  data	  show	  that	  the	  metabolic	  
effects	  of	  RSV	  combined	  with	  its	  antioxidant	  capacities	  makes	  RSV	  particularly	  interesting	  as	  a	  candidate	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Introduction	  
Isolated	   mitochondrial	   complex	   I	   (CI)	   deficiency	   is	   one	   of	   the	   most	   common	   causes	   of	   mitochondrial	  
disease.	  It	  originates	  from	  mutations	  in	  either	  mitochondrial	  or	  nuclear	  DNA	  [1].	  The	  defect	  of	  CI	  usually	  
causes	   progressive	   neuro-­‐degenerative	   disorders,	   which	   explains	   the	   variety	   of	   clinical	   presentations	  
associating	   encephalo-­‐myopathy,	   developmental	   delay,	   hypotonia,	   seizure,	   cardiomyopathy,	   optic	  
atrophy	  and	  other	  organ	   involvement	   [2].	   Interestingly,	  CI	  dysfunction	  also	  has	  been	   implicated	   in	   late-­‐
onset	  neurodegenerative	  disorders	  such	  as	  Parkinson’s	  disease	   [3].	   In	   recent	  years,	  significant	  advances	  
have	  been	  made	  in	  the	  diagnosis	  and	  characterization	  of	  these	  mitochondrial	  disorders.	  In	  particular,	  the	  
implementation	  of	  new	  sequencing	  methods	  has	  facilitated	  the	  identification	  of	  numerous	  disease	  genes	  
[4].	   In	   contrast,	   the	   physiopathology	   that	   explains	   the	   cellular	   dysfunctions	   remains	   poorly	   understood	  
which	  limits	  treatment	  options.	  	  
Among	  the	  possible	  pathophysiological	  mechanisms	  that	  could	   link	  decreases	   in	  activity	  of	  CI	   to	  cellular	  
dysfunction,	  an	  imbalance	  between	  the	  production	  of	  endogenous	  reactive	  oxygen	  species	  (ROS)	  and	  the	  
antioxidant	  defense	   system	  has	  been	  proposed	   [5].	  Although	   low	  concentrations	  of	  ROS	  can	   serve	  as	  a	  
second	  messenger	   to	   regulate	   diverse	   physiological	   functions,	   overproduction	   of	   ROS	   by	  mitochondria,	  
the	  main	  source	  of	   intracellular	  ROS,	  may	  lead	  to	  oxidative	  damage.	  Thus,	  development	  of	  drugs,	  which	  
can	  maintain	  ROS	  homeostasis,	  might	  be	  useful	  for	  alleviating	  the	  symptoms	  associated	  with	  CI	  deficiency	  
[6,	  7].	  	  
Resveratrol	   is	   a	  polyphenolic	   compound	   that	   is	   proposed	   to	  have	  a	  wide	   range	  of	   beneficial	   effects	  on	  
health	  [8].	  Its	  numerous	  biological	  properties	  have	  been	  studied	  extensively	  to	  understand	  these	  effects.	  
In	  animal	  models	  and	  in	  cell	  cultures,	  resveratrol	  exerts	  diverse	  biological	  effects	  probably	  due	  to	  the	  fact	  
that	   it	  has	  many	  molecular	  targets	  [9].	  Recently,	  we	  have	  shown	  that	  resveratrol	  corrects	  the	  defects	   in	  
oxygen	   consumption	   in	   fibroblasts	   from	   some	   patients	   with	   moderate	   CI-­‐deficiency,	   via	   the	   estrogen	  
receptor	   (ER)	  and	   the	  estrogen-­‐related	   receptor	  alpha	   (ERRα)	  pathways	   [10].	  Resveratrol	  also	  has	  been	  
shown	   to	   exert	   beneficial	   neuroprotective	   effects	   through	   its	   antioxidant	   capacity	   [11].	   However,	   the	  
precise	   molecular	   mechanisms,	   which	   underlie	   the	   antioxidant	   effects	   of	   RSV,	   are	   not	   completely	  
understood.	   	   RSV	   may	   have	   direct	   scavenging	   properties	   or	   it	   may	   induce	   endogenous	   anti-­‐oxidative	  
enzymes	  [11].	  Among	  these	  anti-­‐oxidative	  enzymes,	  the	  mitochondrial	  manganese	  superoxide	  dismutase	  
(SOD2)	  is	  the	  first-­‐line	  antioxidant	  defense	  enzyme	  that	  protects	  cells	  from	  oxidative	  stress	  generated	  in	  
the	   mitochondria.	   Sirtuin	   3	   (SIRT3),	   a	   member	   of	   the	   class	   III	   histone	   deacetylase	   family	   that	   resides	  
primarily	  in	  mitochondria,	  may	  regulate	  many	  aspects	  of	  oxidative	  metabolism	  [12].	  Interestingly,	  several	  
recent	  studies	  showed	  that	  SIRT3	  is	  a	  major	  regulator	  of	  the	  mitochondrial	  adaptive	  response	  to	  stress,	  in	  
particular,	   through	  activation	  of	  SOD2	  by	  deacetylation	   [13-­‐15].	   In	   this	   study,	  we	   tested	   the	  hypothesis	  
that	  RSV	  can	  correct	  CI	  deficiency	  in	  skin	  fibroblasts	  from	  patients	  by	  1)	  relieving	  the	  metabolic	  blockade	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and	  2)	   alleviating	  oxidative	   stress.	  Our	   results	   shed	  new	   light	  on	   the	  molecular	  mechanisms	  underlying	  
these	  effects.	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Materials	  and	  methods	  
Cell	  culture	  
Complex	   I-­‐deficient	   human	   fibroblasts	   were	   obtained	   from	   different	   reference	   centers	   for	   the	  
investigation	   and	   biochemical/molecular	   diagnosis	   of	   mitochondrial	   disorders.	   All	   fibroblasts	   were	  
obtained	  from	  patients	  with	  recessively	  inherited	  isolated	  CI	  deficiency,	  which	  originated	  from	  mutations	  
in	  nuclear	  encoded	  CI	  subunit	  genes,	  as	  summarized	   in	  Table	   I.	  Unless	  otherwise	  mentioned,	  fibroblasts	  
from	   patients	   and	   normal,	   control	   individuals	   were	   cultured	   at	   37°C,	   5%	   CO2	  in	   RPMI	  with	   Glutamax™	  
(Gibco)	   supplemented	   with	   10%	   (V/V)	   fetal	   bovine	   serum	   and	   0.2%	   (V/V)	   primocin	   (Invivogen).	   For	  
treatment,	   the	   medium	   was	   removed	   and	   vehicle	   (0.04%	   DMSO),	   RSV	   (75µM	   trans-­‐RSV,	   Cayman	  
chemical),	   TM-­‐RSV	   (75µM	   trimethoxy-­‐resveratrol,	   Cayman	   chemical)	   or	   RSV	   with	   ICI182780	   (10µM	  
Fulvestrant,	  Sigma)	  or	  with	  XCT790	  (5µM,	  Sigma)	  was	  added	  to	  fresh	  medium	  for	  48h.	  
	  
Oxygen	  consumption	  
Maximal	  Oxygen	  Uptake	  Rates	   (OUR)	  were	  measured	  using	  Oxoplates®OP96U,	  96-­‐well	  microplates	  with	  
integrated	  optical	  oxygen	  sensors	  (PreSens,	  Germany),	  as	  previously	  described	  [10].	  	  
	  
Measurement	  of	  cellular	  ATP	  	  
Fibroblasts	   were	   seeded	   (4000	   cells/well),	   in	   triplicate,	   into	   96-­‐well	   culture	   plates.	   The	   next	   day,	   the	  
medium	  was	  removed	  and	  replaced	  by	  glucose-­‐free	  medium,	  10%	  (V/V)	   fetal	  bovine	  serum,	  0.2%	   (V/V)	  
primocin	   and	   supplemented	   with	   5mM	   galactose.	   This	   procedure	   reveals	   putative	   differences	   in	   ATP	  
content,	  since	  cells	  grown	  in	  galactose	  rely,	  mostly,	  on	  oxidative	  phosphorylation	  to	  produce	  their	  ATP	  [16,	  
17].	   ATP	   levels	   were	   measured	   using	   the	   Luminescent	   ATP	   detection	   assay	   kit	   according	   to	   the	  
manufacturer’s	  instructions	  (Abcam).	  	  
	  
Complex	  I	  enzyme	  activity	  
Complex	  I	  enzyme	  activity	  was	  assayed	  according	  to	  the	  spectrophotometric	  method	  described	  in	  [18].	  
	  
Measurement	  of	  cellular	  reactive	  oxygen	  species	  	  
Total	   levels	   of	   cellular	   ROS	   were	   measured	   using	   2',7'-­‐dichlorodihydrofluorescein-­‐diacetate	   (H2DCFDA,	  
Invitrogen)	   according	   to	   the	  manufacturer's	   recommendations.	   Briefly,	   experiments	  were	   performed	   in	  
24-­‐wells	   in	  which	  cells	  were	   incubated	  with	  5µM	  H2DCFDA	   for	  40min	  at	  37°C.	  Cells	  were	   subsequently	  
washed	   with	   PBS,	   lysed	   and	   transferred	   to	   a	   96-­‐well	   black	   plate	   for	   measurement	   of	   fluorescence	  
intensity	   with	   a	   plate	   reader	   (infinite®M200,	   Tecan).	   The	   results	   were	   normalized	   to	   the	   amount	   of	  
protein	  in	  each	  well.	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SIRT3	  enzyme	  activity	  
Mitochondria	  were	  isolated	  using	  a	  mitochondria	  isolation	  kit	  for	  cultured	  cells	  (Abcam)	  according	  to	  the	  
manufacturer’s	   instructions.	   The	   activity	   of	   mitochondrial	   SIRT3	   enzyme	   was	   then	   measured	   using	   a	  
fluorometric	  SIRT3	  activity	  assay	  kit	  (Abcam)	  according	  to	  the	  manufacturer’s	  recommendations.	  
	  
Western	  blot	  analysis	  
Western	  blots	  were	  performed	  as	  previously	  described	  [10].	  Briefly,	  cell	  protein	  extracts	  (15-­‐20µg)	  were	  
resolved	   by	   12%	   SDS-­‐PAGE	   and	   transferred	   to	   PVDF	   membranes.	   Proteins	   were	   detected	   with	   the	  
following	  antibodies:	  SOD2	  (Abcam);	  SIRT3	  (Cell	  Signaling)	  and	  β-­‐actin	  (Millipore).	  
	  
Superoxide	  dismutase	  2	  enzyme	  activity	  
Determination	  of	  superoxide	  dismutase	  (SOD)	  enzyme	  activity	  in	  fibroblasts	  was	  performed	  according	  to	  
the	  spectrophotometric	  method	  of	  Paoletti	  et	  al,	  with	  minor	  modifications	  [19].	  	  
	  
RNA	  interference	  
Small	   interfering	   RNAs	   (siRNAs)	   targeting	   the	   SIRT3	   sequence	   and	   control	   non-­‐target	   siRNAs	   were	  
obtained	  from	  Dharmacon	  (ON-­‐TARGET	  plus	  SMARTpool).	  Fibroblasts	  were	  transfected	  with	  30nM	  siRNAs	  




The	   results	  are	  presented	  as	   the	  mean	  ±	  SEM.	  Differences	  between	  groups	  were	  analyzed	  by	  paired	  or	  
unpaired	  Student’s	  t	  test	  for	  the	  comparison	  of	  two	  groups,	  or	  by	  one-­‐way	  ANOVA	  and	  the	  Fisher	  test	  for	  
comparison	  of	  three	  or	  more	  groups.	  P<0.05	  was	  considered	  significant.	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Results	  
Resveratrol	  corrects	  CI	  deficiencies	  and	  decreases	  intracellular	  ROS	  levels	  
As	  shown	  in	  Fig.	  1A,	  under	  basal	  conditions,	  the	  fibroblasts	  from	  patients	  generally	  exhibited	  a	  significant	  
decrease	  in	  oxygen	  consumption,	  which	  ranged	  from	  extremely	  severe	  (P5)	  to	  relatively	  moderate	  (P10,	  -­‐
25%	  as	  compared	  to	  control).	  This	   is	  consistent	  with	  their	  CI	  deficiencies.	   In	  control	  cells,	  RSV	  increased	  
OUR	  1.5-­‐fold.	   After	   exposure	   to	   RSV,	   8	   of	   the	   13	   patient	   cell	   lines	   exhibited	  marked	   increases	   in	  OUR,	  
from	  +31%	  (Patient	  8)	  to	  +170%	  (Patient	  3).	  Notably,	  nearly	  normal	  OUR	  values	  were	  reached	  in	  five	  cell	  
lines	   (P2,	   P4,	   P8,	   P10	   and	   P13).	   The	   relative	   amounts	   of	   ATP	  were	  measured	   in	   some	   of	   the	   patients’	  
fibroblasts.	  CI	  deficient	  cells	  had	  a	  15	  to	  25%	  reduction	  of	  cellular	  ATP	  content	  (p<0.05)	  as	  compared	  to	  
control	  cells	   (Fig.	  1B).	  Treatment	  with	  RSV	   increased	  the	   level	  of	  ATP	  23%	  in	  the	  control	  cells	  as	  well	  as	  
slightly,	  but	  significantly,	  in	  the	  patients’	  cells.	  For	  the	  rest	  of	  the	  study,	  we	  decided	  to	  use	  the	  CI-­‐deficient	  
cells	  in	  which	  RSV	  treatment	  nearly	  normalized	  OUR	  levels,	  that	  is	  P2,	  P4,	  P8,	  P10	  and	  P13.	  The	  residual	  CI	  
enzyme	  activity	  (in	  the	  absence	  of	  RSV)	  in	  these	  cell	  lines	  ranged	  from	  28%	  (P8)	  to	  56%	  (P10)	  of	  that	  in	  the	  
control	  cells	  (Fig.	  1C).	  After	  treatment	  with	  RSV,	  the	  CI	  activity	  was	  significantly	   increased	  in	  the	  control	  
cells	  (+32%)	  as	  well	  as	  in	  all	  the	  Cl-­‐deficient	  cells	  (from	  +33%	  in	  P2	  and	  P4	  to	  +91%	  in	  P13).	  	  
Excessive	  ROS	  production	  by	  defective	  mitochondria	  often	  has	  been	  proposed	  as	  a	  possible	  mechanism	  to	  
explain	   the	  physiopathology	  of	   respiratory	  chain	  disorders.	  This	   led	  us	   to	   investigate	  whether	  abnormal	  
ROS	  levels	  existed	  in	  the	  same	  five	  cell	  lines	  (P2,	  P4,	  P8,	  P10	  and	  P13).	  We	  found	  that	  all	  five	  CI-­‐deficient	  
cell	  lines	  exhibited	  levels	  of	  intracellular	  ROS	  that	  were	  significantly	  higher	  than	  those	  found	  in	  the	  control	  
cells,	  although	  to	  different	  extents	  (Fig.	  1D).	  P10	  displayed	  a	  1.3-­‐fold	  increase	  in	  ROS	  production	  whereas	  
a	   6-­‐fold	   increase	  was	   found	   for	   P8.	   In	   all	   five	   cell	   lines,	   treatment	  with	  RSV	   significantly	   decreased	   the	  
levels	  of	  ROS	  and,	  in	  four	  of	  those	  ROS	  levels	  were	  not	  significantly	  different	  from	  control	  vehicle-­‐treated	  
cells.	  	  
	  
Resveratrol	   increases	   the	   amount	   of	   SOD2	   protein	   via	   the	   ER	   and	   ERRα	   signaling	   pathways	   in	   human	  
fibroblasts	  	  
Since	  manganese	  superoxide	  dismutase	  (SOD2)	  is	  known	  to	  play	  a	  crucial	  role	  in	  controlling	  the	  levels	  of	  
ROS	  and	  since	  it	  is	  inducible	  by	  RSV	  in	  several	  cell	  types	  we	  sought	  to	  determine	  whether	  this	  enzyme	  was	  
involved	   in	  the	  decrease	   in	  the	   levels	  of	  ROS	  that	  was	  observed	   in	  the	  RSV-­‐treated	  fibroblasts.	  First,	  we	  
studied	  the	  effects	  of	  RSV	  on	  the	  amount	  of	  SOD2	  protein	  in	  the	  control	  cells	  and	  in	  the	  five	  patient	  cell	  
lines.	  As	  shown	  in	  Fig.2A,	  untreated	  CI-­‐deficient	  cells	  had	  amounts	  of	  SOD2	  that	  were,	  as	  compared	  to	  the	  
levels	  in	  control	  cells,	  comparable	  (P2),	  reduced	  (P4	  and	  P8)	  or	  increased	  (P10	  and	  P13).	  	  However,	  in	  all	  
the	  cell	  lines,	  treatment	  with	  RSV	  markedly	  increased	  the	  amount	  of	  SOD2	  (from	  +25%	  in	  P13	  to	  +90%	  in	  
P4	  in	  the	  CI-­‐deficient	  cells	  and	  +89%	  in	  the	  control	  cells).	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We	  next	   investigated	  the	  molecular	  mechanisms	  that	  could	  account	  for	  the	   increase	  of	  SOD2	  protein	   in	  
response	   to	   RSV	   in	   human	   fibroblasts.	   In	   a	   previous	   study,	  we	   proposed	   that	   RSV	   (75µM),	   acting	   as	   a	  
phytoestrogen,	   up-­‐regulated	   mitochondrial	   oxygen	   consumption	   through	   the	   ER	   [10].	   Since	   SOD2	   is	   a	  
mitochondrial	  protein,	  it	  is	  plausible	  that	  the	  ER	  also	  might	  be	  involved	  in	  the	  regulation	  of	  SOD2.	  To	  test	  
this	  hypothesis,	  we	  treated	  control	  fibroblasts	  with	  the	  specific	  ER	  antagonist	   ICI182780.	  We	  found	  that	  
the	  marked	  increase	  in	  the	  amount	  of	  SOD2	  protein	  that	  was	  triggered	  by	  RSV	  was	  fully	  abolished	  by	  the	  
antagonist	   (Fig.	  2B),	  which	   clearly	   indicates	   the	   involvement	  of	  ER.	  However,	   to	  our	   knowledge,	   the	  ER	  
does	   not	   directly	   regulate	   SOD	   gene	   expression.	   This	   led	   us	   to	   envisage	   another	   hypothesis,	   which	  
involves	  the	  ERRα.	  We	  previously	  reported	  that	  RSV,	  through	  its	  action	  on	  the	  ER,	  is	  a	  potent	  inducer	  of	  
the	  master	  regulator	  of	  mitochondrial	  respiratory	  chain	  and	  biogenesis,	  namely	  the	  ERRα.	  The	  increase	  in	  
the	   amount	   of	   SOD2	   protein	   in	   the	   cells	   produced	   by	   RSV	  was	   totally	   prevented	   by	   the	   specific	   ERRα	  
inverse	   agonist	   XCT790	   (Fig.	   2C).	   This	   result	   demonstrates	   the	   participation	   of	   the	   ERRα in	   the	   RSV	  
signaling	  cascade.	  
	  
Resveratrol-­‐induced	  SOD2	  enzyme	  activity	  is	  under	  SIRT3	  control.	  	  
We	   next	   investigated	   whether	   the	   increase	   of	   SOD2	   protein	   resulted	   in	   an	   increase	   in	   SOD2	   enzyme	  
activity,	  as	  might	  be	  anticipated.	  We	   found	  that	   the	   increase	  of	  SOD2	  protein	   following	   treatment	  with	  
RSV	  was	  accompanied,	  indeed,	  by	  a	  corresponding	  increase	  in	  the	  SOD2	  enzymatic	  activity	  in	  the	  control	  
cells	   (+38%),	   and,	   to	   a	   lesser	   extent,	   in	   P13	   (+18%;	   p<0,05)(Fig.	   3A).	   However,	   in	   the	   other	   four	   CI-­‐
deficient	  cell	  lines,	  there	  was,	  surprisingly,	  no	  increase	  in	  SOD2	  enzyme	  activity	  following	  treatment	  with	  
resveratrol.	   This	   puzzling	   observation	   could	   be	   explained	   if	   SOD2	   is	   subjected	   to	   a	   post-­‐translational	  
modification.	  We	  hypothesized	  that	  if	  this	  is	  the	  case,	  the	  post-­‐translational	  mechanism,	  which	  increases	  
SOD2	  enzyme	  activity	   in	   control	   cells,	  might	  be	  dysfunctional	   in	   some	  CI-­‐deficient	   cells.	   In	   this	   respect,	  
several	  recent	  articles	  have	  shown	  that	  Sirtuin-­‐3	  (SIRT3),	  a	  major	  mitochondrial	  NAD+	  dependent	  protein	  
deacetylase,	  directly	  activates	  SOD2	  via	  protein/lysine	  deacetylation	  [13-­‐15].	  	  Of	  crucial	  importance	  is	  the	  
fact	   that	  SIRT3	   is	  a	  NAD+	  dependent	  protein.	  Since	  the	  available	  NAD+	  pool	  might	  be	  a	   limiting	   factor	   in	  
some	  CI-­‐deficient	  cells,	  this	  could	  explain	  the	  absence	  of	  increase	  of	  SOD2	  activity	  in	  these	  cells	  following	  
treatment	  with	  RSV.	  Thus,	  to	  determine	  whether	  the	  increase	  in	  SOD2	  enzyme	  activity	  is	  dependent	  upon	  
SIRT3	  in	  human	  fibroblasts,	  we	  inactivated	  SIRT3	  in	  control	  cells	  by	  knock	  down	  and	  measured	  the	  SOD2	  
enzyme	  activity	  following	  treatment	  with	  RSV.	  The	  suppression	  of	  SIRT3	  expression	  by	  specific	  siRNAs	  was	  
confirmed	  by	  western	  blot	  (Fig.	  3B).	  Knocking	  down	  SIRT3	  prevented	  the	  increase	  in	  SOD2	  enzyme	  activity	  
due	  to	  treatment	  with	  RSV	  in	  control	  cells	  (Fig.	  3C),	  which	  indicates	  that	  SIRT3,	  indeed,	  is	  involved	  in	  the	  
signaling	  pathway	  that	  mediates	  the	  effects	  of	  RSV.	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RSV	   significantly	   upregulated	   SIRT3	   protein	   levels	   in	   control	   cells	   (Fig.	   3B).	   Therefore,	  we	   hypothesized	  
that	   the	  absence	  of	   increase	   in	  SOD2	  enzyme	  activity	   in	   response	   to	  treatment	  with	  RSV	   in	  CI-­‐deficient	  
cells	  was	  due	  to	  an	  absence	  of	   increase	   in	  SIRT3	  protein	   levels.	  However,	  western	  blot	  analysis	  showed	  
that	   treatment	   with	   RSV	   significantly	   increased	   SIRT3	   protein	   levels	   in	   control	   cells	   and	   in	   all	   the	   CI-­‐
deficient	  cells	  (Fig.	  3D).	  Taken	  together,	  the	  results	  support	  the	  notion	  that	  the	  lack	  of	   increase	  in	  SOD2	  
activity	   in	   the	   CI-­‐deficient	   cells	   following	   treatment	   with	   resveratrol	   could	   be	   due	   to	   defective	   SIRT3	  
activity,	   possibly	   linked	   to	   the	   low	  NAD+	   availability	   in	   these	   cells.	   Consistent	  with	   this	   hypothesis,	   we	  
found	   no	   significant	   increase	   in	   SIRT3	   enzyme	   activity	   in	   patients’	   cells	   following	   treatment	   with	   RSV,	  
whereas	  control	  fibroblasts	  treated	  with	  RSV	  exhibited	  a	  39%	  increase	  in	  enzyme	  activity	  (Fig.	  3E).	  Finally,	  
we	   investigated	   the	   possible	   involvement	   of	   ERRα 	   in	   the	   up-­‐regulation	   of	   SIRT3	   protein	   following	  
treatment	  with	  RSV.	  The	   increase	   in	  the	  amount	  of	  SIRT3	  protein	  observed	   in	  response	  to	  treatment	  of	  
control	   cells	   with	   RSV	   was	   fully	   abolished	   by	   the	   ERRα	   inverse	   agonist	   XCT790	   (Fig.	   3F).	   This	   strongly	  
suggests	  that	  ERRα	  is	  involved	  in	  the	  signal	  transduction	  pathway.	  	  
	  
Resveratrol	  but	  not	  Trimethoxy-­‐resveratrol	  decreases	  ROS	  levels	  	  
On	  the	  basis	  of	  our	  results,	  we	  propose	  a	  signaling	  cascade	  (Fig.	  4A),	  which	  accounts	  for	  the	  effects	  of	  RSV	  
on	  SOD2	  and	  SIRT3	  in	  human	  fibroblasts.	  However,	  if	  this	  scheme	  is	  correct	  the	  decrease	  in	  the	  levels	  of	  
ROS	   following	   treatment	   of	   CI-­‐deficient	   fibroblasts	   with	   RSV	   (Fig.	   1C)	   cannot	   be	   explained	   by	   the	  
scavenging	  action	  of	  SOD2,	  which	  is,	  potentially,	  hampered	  by	  the	  low	  availability	  of	  NAD+.	  Therefore,	  we	  
investigated	   whether	   the	   action	   of	   RSV	   on	   the	   levels	   of	   ROS	   also	   could	   be	   due,	   in	   part,	   to	   its	   direct	  
antioxidant	  properties	  which	  are	  linked	  to	  the	  presence	  of	  the	  phenol	  rings	  in	  the	  chemical	  structure.	  To	  
address	  this	  question,	  we	  compared	  the	  effects	  of	  treatments	  with	  RSV	  and	  TM-­‐RSV	  on	  the	  levels	  of	  ROS	  
in	   control	   and	  CI-­‐deficient	   cells.	   TM-­‐RSV	   is	   a	   compound	   in	  which	   the	   three	  hydroxyl	   groups	  have	  been	  
replaced	   by	   three	   methoxy	   groups,	   which	   strongly	   reduces	   the	   intrinsic	   antioxidant	   properties	   of	   this	  
molecule	  as	  compared	  to	  RSV	  (Fig.	  4B).	  We	  found	  that	  TM-­‐RSV	  failed	  to	  decrease	  the	  levels	  of	  ROS	  in	  both	  
control	   and	   Cl-­‐deficient	   cells	   (Fig.	   4C),	  which	   supports	   the	   hypothesis	   that	   the	   phenol	   ring	   structure	   is	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Discussion	  
Patients	  with	  isolated	  CI	  deficiency	  due	  to	  mutations	  in	  nuclear	  genes	  often	  develop	  severe,	  complex	  and	  
rapidly	  fatal	  phenotypes,	  with	  many	  organs	  involved,	  including	  the	  brain	  and	  central	  nervous	  system	  [2].	  
The	  excessive	  production	  of	  ROS,	  which	   leads	   to	  oxidative	  damages	   in	   affected	   tissues,	  has	  often	  been	  
proposed	   to	   explain	   the	   physiopathology	   of	   these	   devastating	   disorders	   [7].	   Indeed,	   Verkaart	   et	   al.	   [5]	  
demonstrated	  that	  superoxide	  production	  was	  increased	  in	  skin	  fibroblasts	  from	  several	  children	  with	  CI	  
deficiency	   and	   suggested	   that	   the	   extent	   of	   increase	   was	   inversely	   proportional	   to	   the	   amount	   of	   CI	  
residual	  activity.	  In	  this	  study,	  we	  have	  confirmed	  that	  the	  production	  of	  ROS	  is	  increased	  in	  CI-­‐deficient	  
cell	  lines,	  but	  not	  to	  the	  same	  extent	  in	  all	  cases.	  Nevertheless,	  in	  our	  study,	  the	  highest	  level	  of	  ROS	  was	  
found	  in	  the	  cells	  of	  patient	  (P8),	  which	  also	  exhibited	  the	  lowest	  residual	  CI	  activity.	  However,	  since	  the	  
level	  of	  ROS	  in	  the	  cells	  is	  the	  result	  of	  both	  ROS	  production	  and	  ROS	  scavenging,	  the	  antioxidant	  defense	  
system,	   in	  which	  SOD2	  plays	  a	  crucial	   role,	   is	  an	   important	  participant	   in	   the	  determination	  of	   this	   fine	  
balance.	  Thus,	  in	  our	  series	  of	  patients'	  fibroblasts,	  we	  found	  evidence	  that	  the	  extent	  of	  increase	  in	  ROS	  
is	  also	  inversely	  proportional	  to	  the	  SOD2	  enzyme	  activity,	  as	  shown	  by	  patients	  P8	  and	  P10.	  .	  	  
Given	  the	  compelling	  evidence	  that	  RC	  dysfunction	  leads	  to	  oxidative	  stress,	  it	  was	  legitimate	  that	  several	  
laboratories	   tested	   diverse	   antioxidants	   for	   the	   prevention	   of	   oxidative	   damage	   [6,	   7].	   Our	   choice	   to	  
investigate	  the	  effects	  of	  resveratrol	  is	  justified	  for	  several	  reasons.	  First,	  in	  a	  previous	  study,	  we	  showed	  
that	  exposure	  to	  RSV	  corrects	  CI	  deficiency	  in	  the	  cell	  lines	  of	  some	  patients	  [10].	  Using	  a	  new	  panel	  of	  CI-­‐
deficient	  cells,	  our	  work	  here	  extends	  the	  notion	  that	  RSV	  can	  improve	  and	  even	  correct	  the	  defect	  in	  RC	  
flux	   in	   cell	   lines	   harboring	  mutations	   in	   nuclear-­‐encoded	   genes	   for	   CI	   subunits.	   Second,	   RSV	   has	   been	  
shown	  to	  be	  a	  ROS	  scavenger	  via	  its	  direct	  antioxidant	  effects	  as	  a	  polyphenolic	  compound	  [20].	  However,	  
in	   the	   context	   of	   its	   protective	   effects	   against	   oxidative	   damages,	   RSV	   has	   been	   studied	  mainly	   for	   its	  
ability	  to	  up-­‐regulate	  the	  expression	  of	  several	  free	  radical	  scavenging	  enzymes	  [21-­‐23].	  RSV	  induces	  the	  
expression	  of	   SOD2	   in	   several	   rodent	  organs	   including	   the	  brain	   [24],	   and	   in	   several	   cell	   lines	   including	  
neuronal	  cells	  [21,	  22].	  Our	  results	  show	  that	  RSV	  stimulates	  SOD2	  protein	  expression	  in	  both	  control	  and	  
CI-­‐deficient	  fibroblasts	  in	  agreement	  with	  these	  results.	  	  
We	  unraveled	  the	  molecular	  mechanisms	  that	  might	  explain	  the	  increase	  of	  SOD2	  at	  the	  protein	  level	  in	  
human	  fibroblasts.	  We	  showed	  that	  the	  ER	  was	  involved	  by	  demonstrating	  that	  the	  specific	  ER	  antagonist	  
ICI182780	  blocked	  the	  increase	  in	  SOD2	  protein	  induced	  by	  treatment	  with	  RSV.	  Our	  results	  are	  consistent	  
with	  those	  of	  Robb	  and	  Stuart	  [22],	  which	  suggest	  that	  RSV	  interacts	  with	  the	  ER	  to	  upregulate	  SOD2	  in	  
several	   cell	   lines.	   However,	   to	   our	   knowledge,	   our	   data	   is	   first	   that	   has	   permitted	   the	   entire	   signaling	  
pathway	  to	  be	  deciphered.	   Indeed,	  since	  no	  ER-­‐responsive	  element	  has	  been	  identified	  in	  the	  promoter	  
region	   of	   SOD2,	   the	   effect	   of	   the	   ER	   on	   the	   SOD2	   gene	   must	   be	   indirect.	   In	   our	   previous	   study,	   we	  
proposed	   that	   RSV,	   after	   interacting	   with	   the	   ER,	   up-­‐regulated	   the	   expression	   of	   the	   orphan	   receptor	  
ERRα and	  that	  this	  accounted	  for	  the	  coordinated	  increase	  in	  expression	  that	  was	  observed	  for	  all	  of	  the	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mitochondrial	   RC	   proteins	   in	   treated	   cells	   [10].	   Since	   SOD2	   is	   a	   mitochondrial	   protein	   and	   since	   an	  
ERRα responsive	   element	   has	   been	   identified	   in	   its	   promoter	   [25],	   we	   tested	   the	   hypothesis	   that	  
ERRα participates	   in	   the	   signaling	   pathway	   that	   leads	   to	   the	   increase	   in	   SOD2	   protein.	   The	   use	   of	   the	  
inverse	   agonist	   XCT790	   confirmed	   the	   involvement	   of	   the	   ERRα	   and	   led	   us	   to	   propose	   a	   scheme,	  
presented	  Fig.	  4A,	  for	  the	  regulation	  of	  SOD2	  expression.	  	  
Surprisingly,	   the	   measurements	   of	   SOD2	   enzyme	   activity	   revealed	   that	   treatment	   with	   RSV	   did	   not	  
increase	  SOD2	  activity	  in	  most	  CI-­‐deficient	  cells,	  despite	  increases	  in	  SOD2	  protein.	  In	  this	  context,	  Robb	  
et	  al.	  [23]	  have	  proposed	  recently	  that	  functional	  mitochondria	  are	  necessary	  since	  the	  induction	  of	  SOD2	  
protein	  by	  RSV	  was	  accompanied	  by	  increases	  in	  SOD2	  enzyme	  activity	  in	  normal	  PC3	  cells	  but	  not	  in	  rho0	  
PC3	  cells.	  This,	  naturally,	  led	  us	  to	  hypothesize	  a	  role	  for	  SIRT3	  since	  this	  NAD+-­‐dependent	  sirtuin	  recently	  
has	   been	   found	   to	   participate	   in	   a	   novel	   post-­‐translational	   regulation	   of	   SOD2.	   Indeed,	   studies	   from	  
several	   laboratories	  have	   suggested	   that	   SIRT3	  binds	   to,	  de-­‐acetylates,	   and	  activates	  SOD2	   to	   scavenge	  
ROS	   in	   response	   to	   various	   stresses	   [13-­‐15].	   In	   these	   studies,	   two	   crucial	   results	   are	   1)	   that	   over	  
expression	  of	  SOD2	  protein	  reduces	  cellular	  ROS	  only	  modestly,	  and	  2)	  that	  SIRT3	  activity	  is	  mandatory	  for	  
the	   induction	  of	  SOD2	  activity	  by	  deacetylation.	   Importantly,	   the	   removal	  of	  NAD+,	  or	   the	  addition	  of	  a	  
sirtuin	  inhibitor,	  prevented	  the	  deacetylation	  of	  SOD2	  and	  its	  subsequent	  activation	  [13-­‐15].	  
We	   found	   here	   that	   although	   CI	   enzyme	   activities	  were	   significantly	   increased	   by	   RSV	   treatment	   of	   CI	  
deficient	  cells,	  they	  were	  not	  restored	  to	  the	  levels	  of	  normal	  control	  cells.	  Therefore,	  we	  propose	  that,	  in	  
the	  patients’	  cell	  lines,	  SOD2	  enzyme	  activity	  is	  not	  fully	  restored	  because	  the	  CI	  enzyme	  activity	  remains	  
too	  low	  to	  completely	  replete	  the	  mitochondrial	  NAD+	  pool,	  which	  is	  limiting	  for	  NAD+-­‐dependent	  sirtuin	  
activity.	   It	   would	   therefore	   be	   very	   interesting	   to	   measure	   the	   NAD+	   concentration	   in	   isolated	  
mitochondria	   from	   control	   versus	   patient	   fibroblasts,	   especially	   because	   it	   is	   well	   admitted	   that	   the	  
mitochondrial	   NAD+	   pool	   is	   distinct	   from	   the	   cytosolic	   one	   [26].	   Unfortunately,	   all	   our	   attempts	   to	  
measure	  the	  NAD+	  concentrations	  in	  mitochondria-­‐enriched	  fractions	  from	  the	  various	  CI-­‐deficient	  patient	  
fibroblasts	   were	   hampered	   by	   the	   limited	   amount	   of	   cells	   obtained,	   due	   to	   their	   slow	   growth	   rates.	  
Nevertheless,	   it	   is	   generally	   acknowledged	   that	   inborn	   CI-­‐deficiency	   leads	   to	   impaired	  NADH	   oxidation	  
and	  to	  decreased	  NAD+	  levels	  in	  the	  mitochondrial	  compartment.	  In	  line	  with	  this,	  and	  in	  keeping	  with	  our	  
hypothesis,	  we	   found	   that	  SIRT3	  enzyme	  activity	  was	  not	   increased	  after	   treatment	  of	  CI-­‐deficient	  cells	  
with	  RSV,	  whereas	  a	  significant	  increase	  was	  measured	  in	  control	  cells	  treated	  with	  RSV.	  	  
These	  results	  are	  in	  line	  with	  those	  of	  recent	  articles,	  in	  which	  different	  authors	  highlight	  the	  importance	  
of	   levels	   of	   NAD+	   in	   mitochondrial	   disorders	   and	   surmise	   that	   mitochondrial	   dysfunction	   could	   be	  
ameliorated	   by	   replenishing	   NAD+	   levels	   [27-­‐29].	   Given	   the	   current	   growing	   interest	   of	   researchers	   in	  
sirtuins,	  various	  strategies	  have	  been	  tested	  in	  attempts	  to	  raise	  NAD+	  pool	  at	  the	  cell	  level,	  or	  in	  specific	  
cell	  compartments,	   including	  mitochondria	  [26,	  30].	  These	  approaches	  relied	  either	  on	  supplementation	  
with	  NAD+	  precursors,	  such	  as	  nicotinamide	  riboside	  (NR),	  nicotinamide	  mononucleotide	  (NMN),	  nicotinic	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acid	   (NA),	   or	   nicotinamide	   (NAM),	   or	   were	   based	   on	   treatment	   with	   pharmacological	   inhibitors	   of	  
Poly(ADP	  ribose)	  polymerases	  (PARPs)	  [31].	  Overall,	  variable	  results	  were	  reported	  depending	  on	  the	  cell	  
or	   animal	   model	   considered.	   Thus,	   in	   CI-­‐deficient	   fibroblasts,	   Pirinen	   et	   al.	   demonstrated	   marked	  
increases	  in	  cellular	  NAD+	  after	  treatment	  by	  MRL-­‐45696	  (a	  PARP1/2	  inhibitor)	  [32],	  whereas,	  Felici	  et	  al.	  
reported	   no	   changes	   after	   treatment	   by	   another	   PARP	   inhibitor	   (PJ34)	   [28].	   Altogether,	   these	  
contradictory	   results	   also	  point	  out	   that	   the	   functioning	  and	  balance	  of	  NAD+	  biosynthetic	  machinery	   is	  
complex,	  and	  still	  poorly	  understood	  [26,	  30,	  31,	  33].	  For	   instance,	   it	   is	  admitted	  that	  the	  mitochondrial	  
NAD+	  pool	  is	  relatively	  distinct	  from	  that	  of	  the	  rest	  of	  the	  cell,	  and	  some	  data	  suggest	  that	  mitochondria	  
might	  have	  their	  own	  NAD+	  biosynthetic	  machinery,	  but	  the	  question	  of	  how	  mitochondria	  maintain	  their	  
NAD+	  pool,	  either	  by	  synthetic	  pathways	  or	  by	  exchanges	  with	  the	  cytoplasmic	  compartment,	  is	  not	  fully	  
clarified.	   Importantly,	  these	  notions	  are	   likely	  complicated	  in	  the	  patients'	  fibroblasts	  since	  CI	  deficiency	  
leads	  to	  a	  permanent	  imbalance	  in	  NAD+/NADH	  ratio,	  which	  might	  induce	  chronic	  adaptive	  changes	  in	  the	  
NAD+	   biosynthetic	   pathways.	   Thus,	   although	   NAD+	   replenishment	   might	   form	   the	   basis	   for	   novel	  
promising	   therapies,	   there	   is	   to	   date	  no	   consensus	  on	   the	   strategy	   to	   use	   in	   order	   to	   boost	   cellular	   or	  
mitochondrial	  NAD+	  levels.	  
The	  importance	  of	  SIRT3	  as	  a	  pivotal	  actor	  in	  mitochondrial	  functions	  such	  as	  ATP	  production	  recently	  has	  
been	  highlighted	  in	  several	  reviews	  [12,	  34,	  35].	  As	  previously	  mentioned,	  SIRT3	  also	  has	  been	  proposed	  
to	  modulate	  the	  response	  to	  oxidative	  stress	  by	  reducing	  ROS	  production	  and,	  thus,	  plays	  a	  key	  role	  in	  the	  
regulation	   of	   mitochondrial	   ROS	   homeostasis.	   In	   this	   context,	   the	   finding	   that	   resveratrol	   induces	   the	  
expression	  of	  SIRT3	  is	   important.	  However,	  our	  results	  also	  demonstrate	  that	  the	  up-­‐regulation	  of	  SIRT3	  
expression	   is	   not	   sufficient	   if	   the	   production	   of	   NAD+	   is	   compromised.	   In	   this	   study,	   we	   also	   have	  
unraveled	  the	  molecular	  mechanisms,	  which	  underlie	  the	  increase	  in	  the	  level	  of	  SIRT3	  protein.	  We	  have	  
demonstrated	  the	  participation	  of	  the	  orphan	  receptor	  ERRα	  in	  the	  signaling	  cascade	  targeted	  by	  RSV,	  in	  
agreement	  with	  the	  demonstration	  of	  an	  ERRα	  binding	  site	  in	  the	  promoter	  region	  of	  the	  SIRT3	  gene	  [36].	  
Although	  SIRT3-­‐dependent	  SOD2	  activation	  seems	  to	  be	  inoperative	  in	  CI-­‐deficient	  cells,	  RSV	  nevertheless	  
decreases	  the	  levels	  of	  ROS	  in	  these	  cells.	  Among	  the	  earliest	  biological	  activities	  attributed	  to	  RSV	  were	  
antioxidant	  properties	  that	  are	  linked	  to	  the	  phenol	  ring	  present	  in	  its	  chemical	  structure.	  The	  substitution	  
in	   RSV	   of	   the	   hydroxy	   groups	   by	  methoxy	   groups	   produces	   a	   compound,	  which	   has	   lost	   it	   antioxidant	  
properties,	  and	  demonstrates	  that	  the	  structure	  of	  RSV	  participates	  in	  its	  protective	  effects	  against	  ROS.	  	  
Finally,	  RSV	  has	  been	  reported	  to	  have	  a	  neuro-­‐protective	  effect	  in	  diverse	  neurodegenerative	  disorders	  
such	   as	   Parkinson’s	   disease,	   Alzheimer's	   disease	   and	   Huntington’s	   disease	   [11,	   37],	   all	   of	   which	   are	  
characterized	  by	  mitochondrial	  defects.	  The	  fact	   that	  RSV	  has	  dual	  antioxidant	  properties	   in	  addition	  to	  
being	   able	   to	   stimulate	   residual	   RC	   capacity	   makes	   this	   compound	   a	   very	   nice	   candidate	   for	   the	  
biochemical	  correction	  of	  moderate	  CI	  deficiency.	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Table	  I:	  Genotypes	  of	  the	  respiratory	  CI-­‐deficient	  patients	  
Patients	   Mutated	  gene	   Nucleotide	  changes	  
Amino	  acid	  
substitutions	   References	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Figure	  legends	  
Figure	  1	  Resveratrol	  can	   improve	  CI	  deficiency	  and	  ROS	  accumulation.	  Experiments	  were	  performed	  in	  
control	   and	  CI-­‐deficient	   fibroblasts	  grown	   for	  48	  h	   in	   the	  presence	  of	  75µM	  resveratrol	   (black	  bars),	  or	  
vehicle	   (DMSO,	  white	   bars).	   Oxygen	  Uptake	   Rates	   (OUR)	   per	   106	   cells	   (A).	   Amount	   of	   cellular	   ATP	   (B).	  
Complex	   I	   enzyme	  activity	   (C).	   Total	   cellular	   reactive	  oxygen	   species	   (D).	   Control	   values	   are	   from	   three	  
healthy	   individuals.	   The	   results	   are	   means	   ±	   SEM	   of	   at	   least	   two	   different	   experiments.	   In	   each	  
experiment,	   samples	   were	   run	   in	   triplicate.	   *P<0.05;	   **	   P<0.01;	   ***	   P<0.001	   as	   compared	   to	   vehicle-­‐
treated	  fibroblasts.	  §	  P<0.05;	  §§	  P<0.01;	  §§§	  P<0.001	  as	  compared	  to	  vehicle-­‐treated	  control	  fibroblasts.	  	  
	  
Figure	  2	  The	  ER	  and	  ERRα 	  are	   involved	  in	  the	   increase	  of	  SOD2	  protein	   level	  triggered	  by	  resveratrol.	  
Control	  and	  CI-­‐deficient	  fibroblasts	  (A)	  or	  control	  fibroblasts	  (B,	  C)	  were	  treated	  with	  various	  compounds	  
for	   48h:	   vehicle,	   RSV	   (75µM),	   ER	   antagonist	   ICI182780	   (10µM),	   ERRα	   inverse	   agonist	   XCT790	   (5µM).	  
Representative	  Western-­‐blots	   and	   histograms	   quantifying	   the	   amount	   of	   SOD	   proteins	   are	   shown.	   The	  
results	  are	  the	  means	  ±	  SEM	  for	  n=2	  to	  n=6	  (A,	  B)	  or	  n=4	  (C)	  experiments.	   In	  each	  experiment,	  samples	  
were	  run	  in	  triplicate.	  *P<0.05;	  **	  P<0.01;	  ***	  P<0.001	  versus	  the	  respective	  vehicle-­‐treated	  fibroblasts.	  §	  
P<0.05;	  §§	  P<0.01;	  §§§	  P<0.001	  versus	  control	  fibroblasts	  treated	  with	  vehicle.	  	  
	  
Figure	  3	  Resveratrol	  does	  not	  increase	  SOD2	  enzyme	  activity	  in	  CI-­‐deficient	  fibroblasts:	  involvement	  of	  
SIRT3.	  Control	  and	  CI-­‐deficient	  fibroblasts	  (A,	  D,	  E)	  or	  control	  cells	  (B,	  C,	  F)	  were	  treated	  48h	  with	  various	  
compounds:	   vehicle,	   RSV	   (75µM),	   	   XCT790	   (5µM).	   SOD2	   enzyme	   activity	   in	   control	   and	   CI-­‐deficient	  
fibroblasts	   (A).	   Validation	   of	   the	   SIRT3	   knock	   down	   (B).	   SOD2	   enzyme	   activity	   in	   control	   fibroblasts	  
transfected	  with	   siNon-­‐Target	   (NT)	  or	   siSIRT3	   (n=3	   independent	  experiments)	   48h	  prior	   treatment	  with	  
RSV	   (C).	   Histograms	   of	   the	   amount	   of	   SIRT3	   protein	   	   and	   representative	   western-­‐blots	   (D,	   F).	   SIRT3	  
enzyme	   activity	   in	   control	   and	   CI-­‐deficient	   fibroblasts	   (E).	   The	   results	   are	   the	  means	   ±	   SEM	  of	   at	   least	  
three	  experiments.	  *P<0.05;	  ***	  P<0.001	  versus	   the	  respective	  vehicle-­‐treated	   fibroblasts.	  §	  P<0.05;	  §§	  
P<0.01;	  §§§	  P<0.001	  versus	  control	  fibroblasts	  treated	  with	  vehicle.	  	  
	  
Figure	   4	   Resveratrol	   chemical	   structure	   is	   important	   for	   its	   antioxidant	   action	   in	   CI-­‐deficient	   cells.	  
Proposed	  mechanisms	   for	   the	   effects	   of	   RSV	   on	   ROS	   homeostasis	   (A).	   Chemical	   structures	   of	   RSV	   and	  
trimethoxy-­‐resveratrol	   (TM-­‐RSV)	   (B).	   Control	   and	  CI-­‐deficient	   fibroblasts	  were	   treated	  with	  RSV	  or	   TM-­‐
RSV	  prior	  the	  measurement	  of	  total	  levels	  of	  cellular	  ROS	  using	  H2DCFDA	  (C).	  The	  results	  are	  the	  means	  ±	  
SEM	  of	  at	  least	  two	  experiments.	  In	  each	  experiment,	  samples	  were	  run	  in	  triplicate.	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  *P<0.05;	  **	  P<0.01	  versus	   the	   respective	  vehicle-­‐treated	   fibroblasts.	  §	  P<0.05;	  §§	  P<0.01;	  §§§	  P<0.001	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